| 8.44 -0.19 (-2.2%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 10.85 | 1-year : | 12.78 |
| Resists | First : | 9.29 | Second : | 10.94 |
| Pivot price | 8.85 |
|||
| Supports | First : | 6.62 | Second : | 5.51 |
| MAs | MA(5) : | 7.76 |
MA(20) : | 9.01 |
| MA(100) : | 6.6 |
MA(250) : | 5.37 |
|
| MACD | MACD : | 0 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 38 |
D(3) : | 22.1 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 10.94 | Low : | 2.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PSNL ] has closed above bottom band by 38.6%. Bollinger Bands are 78.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.72 - 8.77 | 8.77 - 8.81 |
| Low: | 7.92 - 7.98 | 7.98 - 8.04 |
| Close: | 8.34 - 8.44 | 8.44 - 8.52 |
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Tue, 11 Nov 2025
Guggenheim Raises Personalis (PSNL) Price Target to $12.00, Main - GuruFocus
Mon, 10 Nov 2025
[8-K] Personalis, Inc. Reports Material Event | PSNL SEC Filing - Form 8-K - Stock Titan
Mon, 10 Nov 2025
Personalis (NASDAQ: PSNL) wins Medicare coverage for NeXT Personal in II–III breast cancer - Stock Titan
Sat, 08 Nov 2025
Personalis, Inc. (NASDAQ:PSNL) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
Fri, 07 Nov 2025
Personalis, Inc. (NASDAQ:PSNL) Released Earnings Last Week And Analysts Lifted Their Price Target To US$8.50 - simplywall.st
Fri, 07 Nov 2025
Personalis, Inc. (NASDAQ:PSNL) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 89 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 31.3 (%) |
| Held by Institutions | 52.3 (%) |
| Shares Short | 7,670 (K) |
| Shares Short P.Month | 7,550 (K) |
| EPS | -1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.15 |
| Profit Margin | -113.7 % |
| Operating Margin | -126.8 % |
| Return on Assets (ttm) | -20.3 % |
| Return on Equity (ttm) | -60.3 % |
| Qtrly Rev. Growth | -23.8 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -0.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -6.6 |
| PEG Ratio | 0 |
| Price to Book value | 3.92 |
| Price to Sales | 9.31 |
| Price to Cash Flow | -16.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|